Chat with us, powered by LiveChat

Global Upstream Bioprocessing Market

Global Upstream Bioprocessing Market Size, Share, and Analysis, By Product (Bioreactors/Fermenters, Cell Culture Products, Bioreactors Accessories, Filters, Bags & Containers, and Others), By Workflow (Cell Culture, Cell Separation, and Media Preparation), By Use Type (Multi-use and Single-use), By Mode (In-house and Outsourced), By End-User (Biopharmaceutical Companies, CDMO & CROs, Research & Academic Institutes, and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034

Published on: Jun-2024
Report Code: FG HC 02035
No. of Pages: 170-350
Report Format: PDF

Global Upstream Bioprocessing Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 14.4% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 12.4 billion and is projected to reach USD 54.4 billion by the completion of 2034.

Product Overview

Upstream bioprocessing refers to the early stages of producing biopharmaceutical products, like therapeutic proteins, vaccines, or antibodies. It includes the process of growing living cells (such as bacteria, yeast, or mammalian cells) in special bioreactors with controlled conditions. These cells have been genetically modified to make the specific biopharmaceutical product. In addition, the upstream process consists of developing cell lines, preparing media, preparing inoculum, and carrying out fermentation or cell culture. Furthermore, variables including pH, temperature, oxygenation, and nutrient availability are observed and adjusted to improve the cell growth and increase the output of production. Thus, the initial stage is important as it lays the groundwork for the subsequent processing steps, in which the desired product is isolated and transformed into its final form for consumption.

Market Highlights

Global Upstream Bioprocessing Market is anticipated to grow at a robust rate, with projections indicating a 14.4% compound annual growth rate (CAGR) between 2024 and 2034

Global upstream bioprocessing market is predicted to achieve a value of USD 54.4 billion in the forecasted period, due to the growing need for biopharmaceuticals as a result of the increasing incidence of chronic illnesses and an aging population on a global scale. The need for bioprocessing technologies is pushed by the growth of innovative therapies and personalized medicine methods. Moreover, innovations in bioprocessing technologies like single-use systems and high-throughput screening methods are also impacting the market. The government's initiatives and laws that promote biopharmaceutical innovation also help to boost the worldwide demand for the upstream bioprocessing market. Therefore, the upstream bioprocessing industry is expected to grow further due to the increasing demand for biopharmaceuticals and ongoing innovations in bioprocessing technology.

Source: Fatpos Global

Global Upstream Bioprocessing Market Segmentation

Bioreactors/Fermenters segment will dominate for being important equipment that facilitates the cultivation and growth of cells and microorganisms

Global upstream bioprocessing market is classified based on Product into Bioreactors/Fermenters, Cell Culture Products, Bioreactors Accessories, Filters, Bags & Containers, and Others. It is projected that the bioreactors/fermenters segment will lead the global upstream bioprocessing market as bioreactors are the primary devices that are used to cultivate living cells or microorganisms to generate biopharmaceutical products such as antibodies, vaccines, and therapeutic proteins. In addition, with the growing interest in biologics, there is a higher demand for more advanced bioreactors to improve control and management of the manufacturing process. In addition, improvements in bioreactor design, such as the incorporation of reusable sensors and data processing capabilities, have increased production output. Furthermore, the demand for mass production of biopharmaceuticals in industrial manufacturing plants requires the use of big bioreactors.

Single-use segment dominates as a result of its flexibility, cost-effectiveness, and lower risk of cross-contamination

Global upstream bioprocessing market is segmented based on Use Type into Multi-use and Single-use. The single-use segment is expected to dominate the global upstream bioprocessing industry due to several benefits it provides as compared to conventional multi-use systems. In addition, disposable bioprocessing systems like bioreactors, mixers, and containers are created for one-time use, which removes the need for long and expensive cleaning and sterilization procedures. This leads to less time offline and low operational expenses. Besides, disposable systems reduce the chances of cross-contamination, thereby improving the quality and safety of products. Furthermore, the growing use of single-use technologies supports the commitment of the industry to sustainability by lowering water and energy use to lessen environmental impact.

Source: Fatpos Global

Market Dynamics

Growth Drivers

Advancements in Biotechnology are Expected to Foster Market Expansion

Growth of biotechnology is transforming the pharmaceutical and biopharmaceutical sectors. The development of new biological products, such as monoclonal antibodies, vaccines, and gene therapies, has played a major role in boosting the growth of the global upstream bioprocessing market. Moreover, an increase in biosimilars, which are biologic items that closely resemble already approved bioprocessing technologies, is also playing a very important role in increasing the adoption of upstream bioprocessing. Furthermore, biotech businesses are investing in new technology to boost the efficiency of production and ensure regulatory compliance.

Increasing Demand for Personalized Medicine and Targeted Therapies Will Aid in the Adoption of Upstream Bioprocessing Market

Increase in the demand for customized medicine and treatments is a major factor that contributes to the growth of the global upstream bioprocessing market. Personalized medical treatments based on individual genetic makeup involve the creation of unique biological medications in custom-made quantities. This requires advanced bioprocessing techniques upstream to guarantee effectiveness and accuracy. In the same manner, special treatments that target specific disease mechanisms can be complicated and involve biologics such as monoclonal antibodies and cell therapies. Thus, to ensure high yield and quality, advanced bioprocessing technologies are required for these complex treatments. Besides, the trend towards tailored medical solutions increases the demand for advanced bioprocessing equipment and analytics, which is responsible for driving the growth of the market.


High Cost and Complexity Associated with Bioprocessing Equipment

One major constraint on the global upstream bioprocessing market is the high cost and complexity of bioprocessing equipment and operations. Developing and sustaining advanced bioprocessing facilities require large capital investment in modern bioreactors, sensors, and automation systems. In addition, operational costs are expensive due to the requirement for highly skilled personnel and ongoing quality control methods. These financial and operational costs might be highly expensive for smaller biopharmaceutical businesses and startups, which limits their capacity to penetrate the market. As a result, these economic and technical boundaries serve as important limitations.

Recent Developments

  • In April 2023, Merck KGaA launched Ultimus, a single-use process container film, to provide superior strength & leak resistance in single-use assemblies.
  • In October 2023, Getinge announced an agreement to acquire the complete shares of Purity New England, Inc. Purity New England Inc. is a market leader in single-use technologies for bioprocessing applications.
  • In June 2023, Cytiva collaborated with Culture Biosciences to provide advanced upstream bioprocessing solutions to ensure the use of an in-silicon approach and digitalization, along with virtual monitoring with control experiments. This collaboration is anticipated to boost the usage of digital technologies in bioprocessing for flexible, fast, and cost-effective scaling.
  • In May 2023, Entegris and Agilitech collaborated to transform single-use technologies. Agilitech offers highly scalable, flexible, and future-proof single-use technologies for bioprocessing.

Global Upstream Bioprocessing Market

Key Players:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Sartorius AG
  • Danaher Corporation
  • GE Healthcare
  • Lonza Group Ltd.
  • Eppendorf AG
  • Corning Incorporated
  • Applikon Biotechnology BV
  • PBS Biotech, Inc.
  • Novasep Holding SAS
  • Fujifilm Diosynth Biotechnologies (a subsidiary of Fujifilm Holdings Corporation)
  • MilliporeSigma (the Life Science business of Merck KGaA)
  • Bio-Rad Laboratories, Inc.
  • Repligen Corporation
  • Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Global upstream bioprocessing market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The global upstream bioprocessing market is led by North America, with a strong focus on the United States, due to its thriving biotechnology industry and advanced technology resources. This region has a strong bioprocessing ecosystem, with top pharmaceutical and biotech firms, along with renowned research centers.

Furthermore, increasing investments in biopharmaceutical manufacturing and research capabilities are driving major growth in the upstream bioprocessing market in the Asia-Pacific region. Nations such as China and India provide affordable manufacturing solutions and are improving their research and development skills. Besides, the growth of the Asia-Pacific region is due to its ability to meet domestic and global demand for biopharmaceuticals through contract manufacturing and research services.

Source: Fatpos Global

Impact of COVID-19 on the Global Upstream Bioprocessing Market

Global upstream bioprocessing market underwent major changes due to the COVID-19 pandemic, which accelerated growth and innovation. The urgent need for vaccines and treatments led to record-breaking investments in bioprocessing infrastructure. In addition, companies expanded their production capacities by implementing advanced processes in the early stages to fulfill the global demand for billions of vaccine doses. Moreover, the pandemic highlighted the need for strong supply chains and innovative biomanufacturing methods, which led to high cooperation within the industry and backing from governmental entities. However, the attention given to COVID-19-associated bioprocessing temporarily shifted resources away from other biopharmaceutical projects, which resulted in delays in certain areas.

Global Upstream Bioprocessing Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
  • Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
  • Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Global Upstream Bioprocessing Market Scope and Segments:



Study Period


Base Year


Forecast Period


Historical Period


Growth Rate

CAGR of 14.4% from 2024-2034


Value (USD Billion)


Main Segments List

By Product

  • Bioreactors/Fermenters
  • Cell Culture Products
  • Bioreactors Accessories
  • Filters
  • Bags & Containers
  • Others

By Workflow

  • Cell Culture
  • Cell Separation
  • Media Preparation
  • Others

By Use Type

  • Multi-use
  • Single-use

By Mode

  • In-house
  • Outsourced

By End-User

  • Biopharmaceutical companies  
  • CDMO and CROs
  • Research and academic institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions (FAQ):

Global upstream bioprocessing market size was valued at USD 12.4 billion in 2023 and is projected to reach the value of USD 54.4 billion in 2034, exhibiting a CAGR of 14.4% during the forecast period.

The global upstream bioprocessing market refers to the equipment, technologies, and services utilized in the production of biopharmaceuticals and biological products, driving advancements in biomanufacturing for therapeutic development and industrial applications.

The Bioreactors/Fermenters segment and the Single-use segment accounted for the largest Global Upstream Bioprocessing Market share.

Key players in the Global Upstream Bioprocessing Market include Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Danaher Corporation, GE Healthcare, Lonza Group Ltd., Eppendorf AG, Corning Incorporated, Applikon Biotechnology BV, PBS Biotech, Inc., Novasep Holding SAS, Fujifilm Diosynth Biotechnologies (a subsidiary of Fujifilm Holdings Corporation), MilliporeSigma (the Life Science business of Merck KGaA), Bio-Rad Laboratories, Inc., Repligen Corporation, and Other Prominent Players.

Advancements in biotechnology and increasing demand for personalized medicine are the factors driving the global upstream bioprocessing market.

Select License Type


Report accessible by 1 user only

In case you require a hard copy, there will be an additional charge of $500. Please email us at with your request

Call us

Research Assistance

US : +1 (716) 218-3733
UK : +44 (208) 1235555

Select License Type


Report accessible by 1 user only

Sample Request

Client Testimonials